Cocrystal PharmaCOCP
Market Cap: $17.9M
About: Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Employees: 12
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
43% more capital invested
Capital invested by funds: $1.1M [Q1] → $1.57M (+$474K) [Q2]
1.05% less ownership
Funds ownership: 7.68% [Q1] → 6.63% (-1.05%) [Q2]
13% less funds holding
Funds holding: 16 [Q1] → 14 (-2) [Q2]
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Raghuram Selvaraju 44% 1-year accuracy 122 / 277 met price target | 298%upside $7 | Buy Maintained | 22 Aug 2024 |